Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Cresco Labs (CRLBF) over the last 6 years, with Q3 2025 value amounting to -$3.7 million.

  • Cresco Labs' Change in Receivables fell 16024.1% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 4040.53%. This contributed to the annual value of $1.7 million for FY2024, which is 6775.94% down from last year.
  • According to the latest figures from Q3 2025, Cresco Labs' Change in Receivables is -$3.7 million, which was down 16024.1% from $5.7 million recorded in Q2 2025.
  • Cresco Labs' Change in Receivables' 5-year high stood at $14.2 million during Q4 2023, with a 5-year trough of -$10.5 million in Q2 2023.
  • Its 5-year average for Change in Receivables is -$514421.1, with a median of -$1.9 million in 2021.
  • The largest annual percentage gain for Cresco Labs' Change in Receivables in the last 5 years was 38000.0% (2023), contrasted with its biggest fall of 31798.01% (2023).
  • Cresco Labs' Change in Receivables (Quarter) stood at $3.1 million in 2021, then tumbled by 261.57% to -$5.1 million in 2022, then soared by 380.0% to $14.2 million in 2023, then tumbled by 60.45% to $5.6 million in 2024, then tumbled by 165.41% to -$3.7 million in 2025.
  • Its last three reported values are -$3.7 million in Q3 2025, $5.7 million for Q2 2025, and $6.8 million during Q1 2025.